References
- World Health Organization (WHO). A strategic framework for emergency preparedness [Internet]. [cited 2021. Aug 10]. Available from: https://www.who.int/publications-detail-redirect/a-strategic-framework-for-emergency-preparedness
- World Health Organization (WHO). International health regulations: 2005. 2nd. ed. Geneva: WHO; 2008.
- Miglietta A, Waure C. d, Chronaki C, et al. Health technology assessment applied to emergency preparedness: a new perspective. International Journal of Technology Assessment in Health Care. 2021. [cited 2021 Aug 9]. p. 37. Available from: http://www.cambridge.org/core/journals/international-journal-of-technology-assessment-in-health-care/article/health-technology-assessment-applied-to-emergency-preparedness-a-new-perspective/7B483504919FEFAB582A3A7FB3FA2C4C.
- Boutayeb A. The burden of communicable and non-communicable diseases in developing countries. In: Preedy VR, Watson RR, editors. Handbook of disease burdens and quality of life measures. New York (NY): Springer; 2010. Available from: https://doi.org/https://doi.org/10.1007/978-0-387-78665-0_32
- Remais JV, Zeng G, Li G, et al. Convergence of non-communicable and infectious diseases in low- and middle-income countries. Int J Epidemiol. 2013;42(1):221–227.
- Lee ACK, Booth A, Challen K, et al. Disaster management in low- and middle-income countries: scoping review of the evidence base. Emerg Med J. 2014;31(e1):e78–e83.
- Tanveer F, Khalil AT, Ali M, et al. Ethics, pandemic and environment; looking at the future of low middle income countries. Int J Equity Health. 2020;19(1):182.
- Tansley G, Schuurman N, Amram O, et al. Spatial access to emergency services in low- and middle-income countries: a GIS-based analysis. PLOS One. 2015;10(11):e0141113.
- Zhang J, Lu X, Jin Y, et al. Hospitals' responsibility in response to the threat of infectious disease outbreak in the context of the coronavirus disease 2019 (COVID-19) pandemic: implications for low- and middle-income countries. Glob Health J. 2020;4(4):113–117.
- Mitiku AD, Argaw MD, Desta BF, et al. Pertussis outbreak in Southern Ethiopia: challenges of detection, management, and response. BMC Public Health. 2020;20(1):1223.
- Aruna A. Ebola virus disease outbreak — democratic republic of the Congo, August 2018–November 2019. MMWR Morb Mortal Wkly Rep [Internet]. 2019. [cited 2021 Aug 6];68. Available from: https://www.cdc.gov/mmwr/volumes/68/wr/mm6850a3.htm.
- Bausch DG. The need for a new strategy for ebola vaccination. Nat Med. 2021;27(4):580–581.
- 2014-2016 Ebola Outbreak in West Africa | History | Ebola (Ebola Virus Disease) | CDC [Internet]. 2020 [cited 2021 Sep 11]. Available from: https://www.cdc.gov/vhf/ebola/history/2014-2016-outbreak/index.html.
- Chowell G, Hengartner NW, Castillo-Chavez C, et al. The basic reproductive number of ebola and the effects of public health measures: the cases of Congo and Uganda. J Theor Biol. 2004;229(1):119–126.
- Lekone PE, Finkenstädt BF. Statistical inference in a stochastic epidemic SEIR model with control intervention: Ebola as a case study. Biometrics. 2006;62(4):1170–1177.
- Congo Population 2021. Worldometer [Internet]. [cited 2021 Aug 11]. Available from: https://www.worldometers.info/world-population/congo-population/.
- Democratic Republic of the Congo Life expectancy at birth, 1950-2020 - knoema.com [Internet]. Knoema. [cited 2021. Aug 11]. Available from: https://knoema.com//atlas/Democratic-Republic-of-the-Congo/topics/Demographics/Age/Life-expectancy-at-birth.
- 92 low- and middle-income economies eligible to get access to COVID-19 vaccines through Gavi COVAX AMC [Internet]. [cited 2021. Sep 12]. Available from: https://www.gavi.org/news/media-room/92-low-middle-income-economies-eligible-access-covid-19-vaccines-gavi-covax-amc.
- Haakenstad A, Birger M, Singh L, et al. Vaccine assistance to low- and middle-income countries increased to $3.6 billion in 2014. Health Aff. 2016;35(2):242–249.
- Tagoe ET, Sheikh N, Morton A, et al. COVID-19 vaccination in lower-middle income countries: national stakeholder views on challenges, barriers, and potential solutions. Front Public Health. 2021;9:709127.
- Wells CR, Pandey A, Parpia AS, et al. Ebola vaccination in the democratic republic of the Congo. Proc Natl Acad Sci USA. 2019;116(20):10178–10183.
- Fleurence RL, Hollenbeak CS. Rates and probabilities in economic modelling: transformation, translation and appropriate application. Pharmacoeconomics. 2007;25(1):3–6.
- Emerson J, Kim DD. Global Health CEA – DALY Calculator [Internet]. Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, MA.; 2018. [cited 2021 Aug 9]. Available from: http://ghcearegistry.org/orchard/daly-calculator.
- Fox-Rushby JA, Hanson K. Calculating and presenting disability adjusted life years (DALYs) in cost-effectiveness analysis. Health Policy Plan. 2001;16(3):326–331.
- GEVIT_guidance_AppendixK.pdf [Internet]. [cited 2021. Aug 6]. Available from: https://www.who.int/csr/resources/publications/ebola/GEVIT_guidance_AppendixK.pdf?ua=1.
- Ebola-vaccines-prices-11012021.pdf [Internet]. [cited 2021. Aug 6]. Available from: https://www.unicef.org/supply/media/6956/file/Ebola-vaccines-prices-11012021.pdf.
- US Consumer Price Index: Medical Care [Internet]. [cited 2021. Sep 11]. Available from: https://ycharts.com/indicators/us_consumer_price_index_medical_care.
- Marseille E, Larson B, Kazi DS, et al. Thresholds for the cost–effectiveness of interventions: alternative approaches. Bull World Health Organ. 2015;93(2):118–124.
- Vos T, Allen C, Arora M, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the global burden of disease study 2015. Lancet. 2016;388(10053):1545–1602.
- Henao-Restrepo AM, Camacho A, Longini IM, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (ebola Ça suffit!). The Lancet. 2017;389(10068):505–518.
- Vogel G. Rapid test for Ebola now available [Internet]. Science AAAS. 2015 [cited 2021 Aug 11]. Available from: https://www.sciencemag.org/news/2015/02/rapid-test-ebola-now-available
- Bartsch SM, Gorham K, Lee BY. The cost of an ebola case. Pathog Glob Health. 2015;109(1):4–9.
- Seo MK, Baker P, Ngo KN-L. Cost-effectiveness analysis of vaccinating children in Malawi with RTS,S vaccines in comparison with long-lasting insecticide-treated nets. Malar J. 2014;13:66.
- Hagens A, İnkaya AÇ, Yildirak K, et al. COVID-19 vaccination scenarios: a cost-effectiveness analysis for Turkey. Vaccines. 2021;9(4):399.
- Suárez E, Smith JS, Bosch FX, et al. Cost-effectiveness of vaccination against cervical cancer: a multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios. Vaccine. 2008;26:F29–F45.
- Ibuka Y, Paltiel AD, Galvani AP. Impact of program scale and indirect effects on the cost-effectiveness of vaccination programs. Med Decis Making. 2012;32(3):442–446.
- Bodine EN, Cook C, Shorten M. The potential impact of a prophylactic vaccine for ebola in Sierra Leone. Math Biosci Eng. 2018;15(2):337–359.
- Huber C, Finelli L, Stevens W. The economic and social burden of the 2014 ebola outbreak in West Africa. J Infect Dis. 2018;218(suppl_5):S698–S704.
- Kirigia JM, Muthuri RNDK, Muthuri NG. The monetary value of human lives lost through ebola virus disease in the democratic republic of Congo in 2019. BMC Public Health. 2019;19(1):1218.
- Treatment | Ebola (Ebola Virus Disease) | CDC [Internet]. 2021. [cited 2021 Sep 17]. Available from: https://www.cdc.gov/vhf/ebola/treatment/index.html.
- Ehreth J. The global value of vaccination. Vaccine. 2003;21(7–8):596–600.
- Kaslow DC. Force of infection: a determinant of vaccine efficacy? Npj Vaccines. 2021;6(1):1–7.
- Screening Patients | For Clinicians | Ebola Virus Disease | CDC [Internet]. 2021. [cited 2021 Aug 22]. Available from: https://www.cdc.gov/vhf/ebola/clinicians/evaluating-patients/index.html.
- Faherty LJ, Doubeni CA. Unintended consequences of screening for ebola. Am J Public Health. 2015;105(9):1738–1739.
- Abo SMC, Smith? R. Modelling the daily risk of ebola in the presence and absence of a potential vaccine. Infect Dis Model. 2020;5:905–917.
- Potluri R, Kumar A, Maheshwari V, et al. Impact of prophylactic vaccination strategies on ebola virus transmission: a modeling analysis. PLOS One. 2020;15(4):e0230406.
- van Hoek AJ, Gay N, Melegaro A, et al. Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine. 2009;27(9):1454–1467.
- Pitman R, Fisman D, Zaric GS, et al. Dynamic transmission modeling: a report of the ISPOR-SMDM modeling good research practices task force-5. Value Health. 2012;15(6):828–834.
- Lorgelly PK, Lawson KD, Fenwick EAL, et al. Outcome measurement in economic evaluations of public health interventions: a role for the capability approach? Int J Environ Res Public Health. 2010;7(5):2274–2289.